Production of chimeric mouse-human antibodies with specificity to human tumor antigens

A chimeric immunoglobulin light chain comprising a variable region and a human constant region wherein:

• (a) a chimeric immunoglobulin that recognizes the human tumor antigen bound by antibody ING-1 is produced when said light chain is combined with a heavy chain;
• (b) the antigen combining site of said chimeric immunoglobulin of part (a) competitively inhibits the binding of antibody ING-1 produced by cell line HB9812 as deposited with the ATCC;
• and
• (c) said chimeric immunoglobulin of part (a) mediates complement-dependent cytolysis or antibody-dependent cellular cytotoxicity of target cells.

A chimeric immunoglobulin comprising two light chains and two heavy chains, each of said heavy chains comprising a variable region and a human constant region, and each of said light chains comprising a variable region and a human constant region, wherein:

• (a) said chimeric immunoglobulin recognizes the human tumor antigen bound by antibody ING-1;
• (b) the antigen combining site of said chimeric immunoglobulin of part (a) competitively inhibits the binding of antibody ING-1 produced by cell line HB9812 as deposited with the ATCC;
• and
• (c) said chimeric immunoglobulin of part (a) mediates complement-dependent cytolysis or antibody-dependent cellular cytotoxicity of target cells.

A process for producing a chimeric immunoglobulin heavy chain, said process comprising:

• (a) culturing a host that is capable of expressing said heavy chain, wherein said heavy chain comprises a variable region and a human constant region wherein
• (i) a chimeric immunoglobulin that recognizes the human tumor antigen bound by antibody ING-1 is produced when said heavy chain is combined with a light chain;
• (ii) the antigen combining site of said chimeric immunoglobulin of part (i) competitively inhibits the binding of antibody ING-1 produced by cell line HB9812 as deposited with the ATCC;
• and
• (iii) said chimeric immunoglobulin of part (i) mediates complement-dependent cytolysis or antibody-dependent cellular cytotoxicity of target cells;
• and
• (b) producing said heavy chain.

A process for producing a chimeric immunoglobulin light chain, said process comprising:

• (a) culturing a host that is capable of expressing said light chain, wherein said light chain comprises a variable region and a human constant region wherein
• (i) a chimeric immunoglobulin that recognizes the human tumor antigen bound by antibody ING-1 is produced when said light chain is combined with a heavy chain;
• (ii) the antigen combining site of said chimeric immunoglobulin of part (i) competitively inhibits the binding of antibody ING-1 produced by cell line HB9812 as deposited with the ATCC;
• and
• (iii) said chimeric immunoglobulin of part (i) mediates complement-dependent cytolysis or antibody-dependent cellular cytotoxicity of target cells;
• and
• (b) producing said light chain.

A process for producing a chimeric immunoglobulin, said process comprising:

• (a) culturing a host capable of expressing said chimeric immunoglobulin, wherein said chimeric immunoglobulin comprises two light chains and two heavy chains, each of said heavy chains comprising a variable region and a human constant region, and each of said light chains comprising a variable region and a human constant region, wherein:
• (i) said chimeric immunoglobulin recognizes the human tumor antigen bound by antibody ING-1,
• (ii) the antigen combining site of said chimeric immunoglobulin of part (i) competitively inhibits the binding of antibody ING-1 produced by cell line HB9812 as deposited with the ATCC;
• and
• (iii) said chimeric immunoglobulin of part (i) mediates complement-dependent cytolysis or antibody-dependent cellular cytotoxicity of target cells.
• and
• (b) producing said chimeric immunoglobulin.